<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Primary and acquired resistance to anti-epidermal growth factor receptor (EGFR) drugs are clinically relevant problems in patients with metastatic colorectal <z:mp ids='MP_0002038'>carcinoma</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>A complex network of molecular alterations is involved in this phenomenon </plain></SENT>
<SENT sid="2" pm="."><plain>Bertotti et al. report the development of serially transplantable groups of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> xenografts in immune-deficient mice from patient-derived, genetically characterized metastatic colorectal <z:mp ids='MP_0002038'>carcinoma</z:mp> samples </plain></SENT>
<SENT sid="3" pm="."><plain>These experimental models ("xenopatients") might represent a novel approach to discover and characterize the mechanisms of resistance to anti-EGFR therapy and other molecularly targeted therapies in metastatic colorectal <z:mp ids='MP_0002038'>carcinoma</z:mp> </plain></SENT>
<SENT sid="4" pm="."><plain>In this respect, Bertotti et al. were able to identify HER2 gene amplification as one such mechanism of resistance to anti-EGFR therapy </plain></SENT>
</text></document>